Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) is reporting second quarter financial results on Tuesday 11th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, SNSS is expected to report 2Q20 loss of $ 0.06 per share from revenue of $ 0.19 million.
For the full year, analysts anticipate top line of $ 0.54 million, while looking forward to loss of $ 0.2 per share bottom line.
Previous Quarter Performance
Sunesis Pharmaceuticals, Inc. announced loss for the first quarter of $ 0.05 per share, from the revenue of $ 0.12 million. The quarterly revenues lowered 73.33 percent compared with the same quarter last year. Street analysts expected Sunesis Pharmaceuticals, Inc. to report loss of $ 0.07 per share on revenue of $ 0.19 million for the first quarter. The bottom line results beat street analysts by $ 0.02 or 28.57 percent, at the same time, top line results fell short of analysts by $ 0.07 million or 36.84 percent.
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of SNSS was $ 0.33, representing a 65.00 % increase from the 52 week low of $ 0.20 and a 70.8 % decrease over the 52 week high of $ 1.13.
The company has a market capital of $ 53.31 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”SNSS” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Recent Analyst recommendations
- On 24th June 2020, downgraded by Oppenheimer to Perform from Outperform rating.
Conference Call
Sunesis Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 11th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.sunesis.com
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Brutons tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia.
